跳至主要内容
MedPath Trial logoMedPath TrialMedPath Trial Home
临床试验/jRCT2031240628
jRCT2031240628进行中（未招募）不适用

Phase II/III study of MD-712

Mochida Pharmaceutical Co., Ltd.0 个研究点目标入组 15 人开始时间: 2025年2月27日最近更新:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

试验速览

阶段
不适用
状态
进行中（未招募）
入组人数
15
主要终点
-
研究概览研究设计入排标准结局指标研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Single Arm Study
干预模型
Single Assignment
主要目的
Treatment Purpose
盲法
Open(masking Not Used)

入排标准

年龄范围
18age old over 至 80age old under（—）
性别
All

入选标准

  • •Patient was diagnosed as either idiopathic or heritable PAH, drug- and toxin-induced PAH,CTD-PAH, HIV-PAH, CHD-PAH or PH associated with ILD or CPFE

排除标准

  • •Patient was diagnosed as PH other than those accepted as outlined in the Inclusion Criteria

结局指标

主要结局

-

Rate of change in pulmonary vascular resistance index

次要结局

未报告次要终点

研究者

相似试验

进行中（未招募）
1 期
A Phase 2 Study of MM-121 in Combination with Chemotherapy versus Chemotherapy Alone in Patients with Heregulin Positive Non-Small Cell Lung Cancer.Heregulin Positive, Locally Advanced or Metastatic Non-Small Cell Lung CancerMedDRA version: 18.1Level: PTClassification code 10059515Term: Non-small cell lung cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 18.1Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
EUCTR2014-003673-42-ESMerrimack Pharmaceuticals, Inc.120
进行中（未招募）
2 期
A study of tucatinib (MK-7119) in combination with trastuzumab and capecitabine in participants with previously treated locally advanced unresectable or metastatic human epidermal growth factor receptor 2 positive (HER2+) breast carcinoma (MK-7119-001)Previously treated locally advanced unresectable or metastatic HER2+ breast carcinoma
JPRN-jRCT2051200152akamura Sosuke55
进行中（未招募）
1 期
A Two Part, Phase I-IIa Study Evaluating MK-1775 in Combination With Topotecan/Cisplatin in Adult Patients With Cervical CancerPatients with advanced, metastatic, and recurrent carcinoma of the uterine cervixMedDRA version: 12.1Level: LLTClassification code 10008229Term: Cervical cancer
EUCTR2009-017054-12-FRMerck & Co., Inc.132
进行中（未招募）
不适用
An Open-Label, Phase II Extension Study of MDX-060 in Patients with Relapsed or Refractory Hodgkin’s Disease Previously Treated in Protocol MDX060-03Relapsed or Refractory Hodgkin’s DiseaseMedDRA version: 5.0Level: LLTClassification code 10020266
EUCTR2004-005040-27-GBMedarex, Inc.
进行中（未招募）
不适用
An Open-Label, Phase II Extension Study of MDX-060 in Patients with Relapsed or Refractory Hodgkin’s Disease Treated in Protocol MDX060-03 - not availableRelapsed or Refractory Hodgkin’s DiseaseMedDRA version: 5.0Level: LLTClassification code 10020266
EUCTR2004-005040-27-DEBristol-Myers Squibb Company84